Abstract
Melanoma is a malignant tumor of neuroectodermal origin with an increasing incidence and mortality. It needs to be detected and eliminated early, because melanoma is characterized by its high resistance to the conventional therapies, including surgery and chemotherapy (1-3). On the other hand, melanoma is supposed to be one of the most immunogenic tumors which is demonstrated by tumor-infiltrating lymphocytes (TIL) destroying melanoma cells (4-6). This may also be responsible for the occurrence of spontaneous partial or complete melanoma regression and for concomitant destruction of melanocytes in benign lesions, leading to clinical phenomena such as halo nevi, uveitis, and vitiligo in melanoma patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmann, D. L., Creagan, E. T., Hahn, R. G., Edmonson, J. H., Bisel, H. F., and Schaid D. J. (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63, 224–227.
Johnson, T. M., Smith, J. W., Nelson, B. R., and Chang A. (1995) Current therapy for cutaneous melanoma. J. Am. Acad. Dermatol. 32, 689–707.
Garbe, C. (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 3, 291–299.
Oettgen, H. F. and Old, L. J. (1991) The history of cancer immunotherapy, in Biologic Therapy of Cancer, Principles and Practice (de Vita, V. T., Hellman, S., and Rosenberg, S. A., eds.), Lippincott, Philadelphia, PA, pp. 87–99.
Parkinson, D. R., Houghton, A. N., Hersey, P., and Borden, E. C. (1992) Biologic therapy for melanoma, in Cutaneous Melanoma (Balch, C. M., Houghton, A. N., Milton, G. W., Sober, A. J., and Soong, S. J., eds.), Lippincott, Philadelphia, PA, p. 522.
Dagleish, A. (1996) The case for therapeutic vaccines. Melanoma Res 6, 5–10.
Mackensen, A., Carcelain, G., Viel, S., Raynal, M.-C., Michalaki, H., Triebel, F., et al. (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93, 1391–1402.
Maeurer, M. J., Storkus, W. J., Kirkwood, J. M., and Lotze, M. T. (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 6, 11–24.
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., et al. (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91, 6458–6462.
Robbins, P. F., El-Gamil, M., Kawakami, Y., and Rosenberg, S. A. (1994) Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54, 3124–3126.
Möller, P. and Schadendorf, D. (1997) Somatic gene therapy and its implication for the treatment of malignant melanoma. Arch. Dermatol. Res. 289, 71–77.
Schadendorf, D. (1997) Cytokines, autologous cell immunostimulatory and gene therapy for cancer treatment, in Skin Immune System 2nd ed. (Bos, J. D., ed.), CRC, Boca Raton, FL, pp. 657–669.
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinhhausen, S. E., et al. (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Engl. J. Med. 313, 1485–1492.
Tepper, R. I., Pattengale, P. K., and Leder, P. (1989) Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 57, 503–512.
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Livitsky, H. I., Simons, J. W., et al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397–403.
Pardoll, D. M. and Beckerleg, A. M. (1995) Exposing the immunology of naked DNA vaccines. Immunity 3, 165–169.
Cayeux, S., Beck, C., Aicher, A., Dörken, B., and Blankenstein, T. (1995) Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25, 2325–2331.
Marcel, T. and Grausz, J. D. (1997) The TMC worldwide gene therapy enrollment report, end 1996. Hum. Gene Ther. 8, 775–800.
Ledley, F. D. (1995) Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 6, 1129–1144.
Schadendorf, D., Czarnetzki, B. M., and Wittig, B. (1995) Clinical protocolinterleukin-7-, interleukin-12-, and GM-CSF gene transfer in patients with metastatic melanoma. J. Mol. Med. 73, 473–477.
Schadendorf, D., Henz, B. M., and Wittig, B. (1996) Interleukin 7 trials for melanoma treatment. Mol. Med. Today 2, 143–144.
Möller, P., Sun, Y. S., Dorbic, T, Möller H., Makki, A., Jurgovsky, K., et al. (1998) Vaccination with IL-7-gene modified autologous melanoma cells can enhances the anti-melanoma lytic activity in peripheral blood of advanced melanoma patients-a clinical phase I study. Brit. J. Cancer, 77, 1907–1916.
Sun, Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., et al. (1998) Vaccination with Il-12-gene modified autologous melanoma cellspreclinical results and a first clinical phase I study. Gene Ther. 5, 481–490.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Schadendorf, D. (2000). Ex Vivo Cytokine Gene Transfer in Melanomas by Using Particle Bombardment. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Medicine™, vol 35. Humana Press. https://doi.org/10.1385/1-59259-086-1:439
Download citation
DOI: https://doi.org/10.1385/1-59259-086-1:439
Publisher Name: Humana Press
Print ISBN: 978-0-89603-714-4
Online ISBN: 978-1-59259-086-5
eBook Packages: Springer Protocols